Medical AI company JLK from Korea has received medical device approval from the Food and Drug Administration of Thailand for its AI brain image analysis solution.
Founded in 2014, this startup offers a wide range of image analysis tools on the Medihub platform, to aid in the diagnosis of neurological diseases and cancer. It also operates other AI-powered platforms for telehealth, medical genomics, and data management, all connected to a cloud system.
WHAT IT DOES
JLK’s Atroscan uses AI to classify and divide 3D brain MRI images into 62 regions and measure cortical thickness and extent of brain atrophy. These results show how well the patient’s brain is aging, which the software can also compare to the averages of people in their age group. Its other functions include personalized reports, analytics and tracking management.
WHY IT IMPORTANT
With its recent launch, JLK continues to expand in Thailand with a focus on providing AI solutions for brain and lung diseases that frequently occur in the elderly. Thailand has a rapidly aging population with elderly people aged 65 and over accounting for about 13.5% of the country’s total population last year.
Last year, the company received a similar license from the Thai FDA for JViewer-X, a lung disease analysis solution, and another license in May this year for the Medihub Brain Aneurysm JBA stroke analysis solution- 01K.
“We will accelerate our entry into the Thai market – the leading medical market in Southeast Asia – through [FDA’s] approved Atroscan, which can be used to analyze degenerative brain diseases such as dementia,” said JLK CEO Dongmin Kim.
SNAPSHOT . MARKET
Korean medical AI developers are increasingly targeting Thailand, the seventh-largest medical device market in Asia-Pacific. Last month, Lunit announced that they are partnering with Fujifilm Thailand to deploy INSIGHT CXR and INSIGHT MMG software at Bumrungrad International Hospital. In June, the Thai FDA approved VUNO’s application to market its AI-based VUNO Med-Chest radiography solution in the country.
In other dementia-related news, Fujifilm has launched a new AI tool that can predict Progression of Alzheimer’s disease among patients with mild cognitive impairment.